Skip to main content

Table 3 Invasive disease-free survival according to UGT2B7His268Tyr genotype and treatment

From: Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer

 

Hazard ratio (95% CI)

Adjuvant chemotherapy

Crude

Adjusted

Epirubicin

2.24 (1.13 to 4.44)

2.64 (1.22 to 5.71)

 

P = 0.021

P = 0.014

Epirubicin/tamoxifen

4.43 (1.34 to 14.6)

5.22 (1.67-26.04)

 

P = 0.015

P = 0.015)

No epirubicin

0.80 (0.43 to 1.49)

0.78 (0.40 to 1.50)

 

P = 0.48

P = 0.45

None

0.80 (0.47 to 1.34)

0.87 (0.49 to 1.55)

 

P = 0.39

P = 0.64

  1. CI, confidence interval.